ATE445395T1 - Verfahren zur unterdrückung der ptx3 genexpression - Google Patents

Verfahren zur unterdrückung der ptx3 genexpression

Info

Publication number
ATE445395T1
ATE445395T1 AT03746454T AT03746454T ATE445395T1 AT E445395 T1 ATE445395 T1 AT E445395T1 AT 03746454 T AT03746454 T AT 03746454T AT 03746454 T AT03746454 T AT 03746454T AT E445395 T1 ATE445395 T1 AT E445395T1
Authority
AT
Austria
Prior art keywords
sup
sub
suppressing
gene expression
ptx
Prior art date
Application number
AT03746454T
Other languages
English (en)
Inventor
Shigeru Morikawa
Akashi Izumi
Takao Hamakubo
Tatsuhiko Kodama
Original Assignee
Kowa Co
Nissan Chemical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co, Nissan Chemical Ind Ltd filed Critical Kowa Co
Application granted granted Critical
Publication of ATE445395T1 publication Critical patent/ATE445395T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03746454T 2002-04-15 2003-04-11 Verfahren zur unterdrückung der ptx3 genexpression ATE445395T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37211402P 2002-04-15 2002-04-15
US10/196,428 US20030195167A1 (en) 2002-04-15 2002-07-17 PTX3-gene expression inhibitor
PCT/JP2003/004603 WO2003086380A1 (en) 2002-04-15 2003-04-11 Ptx3 gene expression suppressing method

Publications (1)

Publication Number Publication Date
ATE445395T1 true ATE445395T1 (de) 2009-10-15

Family

ID=28794074

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03746454T ATE445395T1 (de) 2002-04-15 2003-04-11 Verfahren zur unterdrückung der ptx3 genexpression

Country Status (9)

Country Link
US (2) US20030195167A1 (de)
EP (1) EP1494661B1 (de)
JP (1) JP4409295B2 (de)
AT (1) ATE445395T1 (de)
AU (1) AU2003226456A1 (de)
DE (1) DE60329668D1 (de)
MY (1) MY137134A (de)
TW (1) TWI349547B (de)
WO (1) WO2003086380A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4719572B2 (ja) * 2003-04-17 2011-07-06 興和株式会社 Lklf/klf2遺伝子発現促進剤
WO2005053683A1 (en) 2003-11-26 2005-06-16 Duke University A method of preventing or treating glaucoma
ITRM20030596A1 (it) * 2003-12-23 2005-06-24 Sigma Tau Ind Farmaceuti Uso di inibitori della pentraxina lunga ptx3, per la preparazione di un medicamento per la prevenzione e cura di patologie che rispondono all'inibizione dell'attivita' biologica di detta ptx3.
EP1720014A4 (de) * 2004-02-25 2008-01-16 Perseus Proteomics Inc Verfahren zur beurteilung des ausmasses einer vaskulopathie
CN1946384B (zh) * 2004-04-26 2011-04-20 爱尔康公司 治疗眼高压和青光眼的他汀类
WO2008001499A1 (en) * 2006-06-29 2008-01-03 Kowa Co., Ltd. Prophylactic and/or therapeutic agent for rheumatoid arthritis
CN106950366B (zh) * 2017-02-15 2019-03-22 中国医学科学院北京协和医院 一种acpa阴性的ra诊断标志物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5244916A (en) * 1992-01-31 1993-09-14 The Scripps Research Institute Inhibition of respiratory burst using posttranslational modification inhibitors
WO1999026657A1 (en) * 1997-11-25 1999-06-03 Musc Foundation For Research Development Inhibitors of nitric oxide synthase
CA2365869A1 (en) * 1999-03-08 2000-09-14 Richard D. Tillyer Crystalline hydrated dihydroxy open-acid simvastatin calcium salt
US6403637B1 (en) * 1999-08-09 2002-06-11 Univ Saint Louis Methods of modulating matrix metalloproteinase activity and uses thereof
CA2399396A1 (en) * 2000-02-10 2001-08-16 Yasuo Sugiyama Tnf- .alpha. inhibitors
US20020159974A1 (en) * 2000-09-19 2002-10-31 Francois Mach Treatment of multiple sclerosis with statins (HMG-CoA reductase inhibitors)
CA2422820A1 (en) * 2000-09-19 2002-03-28 Novimmune S.A. Use of statins (hmg-coa reductase inhibitors) for the preparation of medicament as a novel type of immunomodulator, immunosuppressor and anti-inflammatory agent

Also Published As

Publication number Publication date
MY137134A (en) 2008-12-31
TWI349547B (en) 2011-10-01
JP2005522490A (ja) 2005-07-28
EP1494661A1 (de) 2005-01-12
WO2003086380A1 (en) 2003-10-23
AU2003226456A8 (en) 2003-10-27
EP1494661B1 (de) 2009-10-14
US20080161348A1 (en) 2008-07-03
JP4409295B2 (ja) 2010-02-03
DE60329668D1 (de) 2009-11-26
US20030195167A1 (en) 2003-10-16
TW200403990A (en) 2004-03-16
AU2003226456A1 (en) 2003-10-27

Similar Documents

Publication Publication Date Title
DE60301345D1 (de) Stabilisierte askorbinsäurederivate
EA200601830A1 (ru) Ортозамещённые арильные или гетероарильные амидные соединения
TW200519088A (en) Aryl or heteroaryl amide compounds
EA200601847A1 (ru) Замещённые метиларил- или гетероариламидные соединения
NO20055337L (no) Imidazolinkorrosjonsinhibitorer
MY142807A (en) Benzimidazole derivative and use thereof.
EP1063228A4 (de) Cycloalken-derivate, verfahren zu ihrer herstellung und ihre verwendung
ES2124545T3 (es) Azolidindionas como agentes antihiperglucemicos.
ATE426594T1 (de) Verfahren zur herstellung von inhibitoren der hmg-coa-reduktase
ATE402185T1 (de) Verfahren für fluorcytidinderivate
ATE445395T1 (de) Verfahren zur unterdrückung der ptx3 genexpression
EP0879841A3 (de) Organosiliciumverbindung, Verfahren zur Herstellung dieser Verbindung und diese Verbindung enthaltende elektrolumineszente Vorrichtung
ATE207055T1 (de) Verfahren zur herstellung von 4-aryl-3- hydroxymethyl-piperidinen
WO2004080408A3 (en) Method of treating cancer with azaspirane compositions
ATE428693T1 (de) Prostaglandinsynthese
PL235835A1 (de)
YU43902A (sh) Novi razgranati supstituisani amino derivati od 3-amino-1- -fenil-1h(1,2,4) triazola, postupak za njihovo dobijanje i farmaceutski preparati koji ih sadrže
EA200800149A1 (ru) 4,5-диарилпиррольные производные, способ их получения и применение в терапии
DE60140333D1 (de) Lichtempfindliche Verbindung und lichtempfindliches Harz
EA200200682A1 (ru) Новые соединения n-бензилпиперазина, способ их получения и фармацевтические композиции, их содержащие
MXPA05013981A (es) Resolucion de derivados de acido a- (fenoxi) fenilacetico.
EA200100065A1 (ru) Производные гидроксамовой кислоты как ингибиторы продуцирования cd23 человека и высвобождения tnf
DK0504290T3 (da) Inhibitorer af dihydrofylatreduktase fra Pneumocystis carinii
DE602004030091D1 (de) Verfahren zur reduktiven deshalogenierung
GB0316268D0 (en) Process for preparing cyclic organohydrogensiloxanes

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties